IceCure Medical Ltd (ICCM) Earnings Call Transcript
May 12, 2026
Earnings Call Speaker Segments
Thanks, operator. Hi everybody, and thanks for joining the IceCure Medical conference call. Today we'll review the financial results for the three-month period that ended March 31, 2026, and bring you up to date on recent operational highlights. Feel free to follow along using the earnings press release we issued earlier this morning. With us on the call are Eyal Shamir, IceCure Medical's CEO, and Shad Good, the company's VP Sales North America, plus our guest, Dr. Richard Fine, who is a key opinion leader in breast cancer treatment, a breast surgeon, and an ICE3 investigator. He has published and presented ICE3 data, and he stays active in hands-on trainings and symposia focused on cryoablation for the treatment of early-stage breast cancer. To kick things off, let me pause briefly and share a note regarding statements that look ahead. Both this call and the Q&A portion afterward include forward-looking statements, as defined under the safe harbor rules of the Private Securities Litigation Reform Act of 1995, along with other federal securities regulations. Terms like expects, anticipates, intends, plans, believes, seeks, and estimates — as well as comparable wording or forms of those terms — are meant to signal such forward-looking statements. To illustrate, this presentation contains forward-looking statements whenever we talk about IceCure's quickening commercial traction and rising interest in ProSense, the possibility of recurring income, turning expanding demand into installations and system purchases, our anticipation of announcing further increases in active accounts for the second quarter of 2026, our intent to enlarge the U.S. commercial team and sales footprint, and our intentions concerning CPT reimbursement codes. During today's call, any forward-looking statements we make or suggest come with additional risks and uncertainties. A great number of these sit outside the company's ability to control, and they include the ones described under the Risk Factors heading in our annual report on Form 20-F covering the fiscal year that closed on December 31, 2025. That filing went to the Securities and Exchange Commission on March 17, 2026, and you can find it on the SEC's site, www.sec.gov. Unless the law demands it, the company states that it has no plan or duty to refresh or amend any forward-looking statements, whether that would stem from fresh information, later occurrences, or some other cause. What you're hearing on this conference call is time-sensitive, and it reflects only what we know as of today's live broadcast, May 12, 2026. I'll hand things over now to Eyal Shamir, the chief executive at IceCure Medical. Eyal, the floor is yours.
Thanks, Michael, and I appreciate everyone being on the call today. You saw in the press release we put out earlier this morning that 2026 has begun very strongly and encouragingly for us; for the first quarter, we reported revenue growth of 26% year-over-year, with especially strong results in North America, where sales rose by 84%, and in the U.S., where sales grew by 31%, reflecting both in pre system sales and growing utilization of disposable crops. Because time is limited, and since Shad and Dr. Fine will offer additional insight, I'd encourage you to look over our press release for complete financial details. What our results plainly show is accelerating commercial momentum, especially in the U.S. after FDA clearance for low-risk early breast cancer, along with the continued conversion of our growing pipeline in your active customers and the expanding clinical and scientific validation supporting process. In the first quarter, we made meaningful progress across several three areas of our business; from a revenue standpoint, growth came from new system placement and rising sales of disposable probes, which reflects higher procedure volume at both new and existing customer sites. Engagement keeps building across a range of customer types, among them the most prestige large hospital network in the world, regional hospitals network and the specialty and outpatient clinics. A lot of these customers are folding process into their existing workflow, which remains a key advantage of our system, and it doesn't call for additional infrastructure or complex integration; we're also encouraged by increasing procedural activities, an important indicator for long-term adoption and recurring revenue potential. Now to our U.S. commercial progress. The momentum we talked about last quarter is turning into measurable growth. Before FDA approval, we had 13 active accounts, some of them with multiple system installation. Since FDA approval, we've added several new accounts and reactivated others that had gone inactive while waiting FDA clearance. Consequently, we raised our active account base to 19, which is a 46% increase compared to active accounts prior to the FDA approval. This level of growth encourages us, and based on currently available information, we expect to report continued growth in active accounts during the second quarter. This expansion reflects new customers acquisition and rising confidence among existing institutions, many of which are large health care networks where we see meaningful opportunities for additional system placement within our current customers' network. Although the U.S. remains our primary focus, it's important to note that the FDA clearance also has a meaningful global impact. We're seeing increased interest across Europe, Asia and the Americas. That's particularly evident at international medical conferences, where a growing number of physicians and researchers are expressing interest in adopting ProSense and initiating new studies using ProSense for breast cancer; for instance, although ProSense had CE mark approval in Europe for breast cancer for some time, the FDA clearance has had a visible impact on increased interest. The fact that interest is building worldwide like this matches what we anticipated, and it strengthens the case that securing FDA clearance serves as a crucial validation point for what we've built. At this point I'll hand things over to Shad, who's going to share additional details about what we're doing commercially in the U.S. as well as our pipeline. Shad?
Thank you, Eyal. Across the United States, we're witnessing demand for ProSense accelerate in a way that's both clear and significant, and a number of converging factors are driving that. At the recent Society of Breast Imaging and American Society of Breast Surgeons Annual conferences, this marked the first occasion on which we could market ProSense directly for treating breast cancer after receiving FDA clearance. Interest ran substantially above what we'd historically seen, and the count of qualified leads those conferences produced came in substantially above what we saw during 2025, before the FDA clearance. Broader still, at major breast and radiology conferences both in the U.S. and around the world, we're noticing awareness and engagement climbing markedly. Physicians are actively pursuing information, hands-on training and ways to bring cryoablation into their practices. Our belief is that FDA clearance serves as the primary driver behind this heightened interest, with additional support coming from the expanding collection of independent clinical data, the revised ASBrS guidelines that recommend cryoablation for low-risk breast cancer, and the broadening reimbursement framework. Importantly, we now have clear evidence that this rising interest is converting into commercial activity. Leads that came in after FDA clearance are moving through purchasing processes as we speak, and we expect them to turn into system sales and installations during this quarter and in the quarters that follow. Meanwhile, the robust pipeline we're assembling today gives us visibility into sustained growth, since many leads we're generating right now should convert into sales during the second half of 2026 and into early 2027. That leaves us increasingly confident about how durable our growth trajectory is. To keep up with this rising demand, we're growing our U.S. commercial organization, bringing on talented sales representatives to widen our sales footprint. That will put us in a better position to capture market opportunities and to keep cultivating relationships with key institutions nationwide. A further important driver of adoption is our ChoICE post-market study, which secured FDA approval in the first quarter. This study will encompass 30 clinical and commercial hybrid sites throughout the U.S. We plan to announce these sites as they onboard, and we expect the ChoICE study to contribute significantly to speeding up adoption by widening access to ProSense while also producing additional clinical data and supporting our ongoing reimbursement efforts. As a reminder, procedures done with ProSense already have support from an established CPT1 code covering facility costs of roughly $4,000. We also expect to submit the CPT1 code reimbursement covering physician costs in June; we expect to hear back on this in early 2027, and it could result in additional reimbursement by early 2028. We also applied for transitional pass-through payment, which may result in an additional $900 by early 2027 if we qualify. I will now turn the call over to Dr. Richard Fine to provide a clinical perspective. Dr. Fine?
Thanks, Shad. Being an investor in the ICE3 clinical trial, I've had the chance to personally treat patients with ProSense and to track how they did over time. From what I've experienced, the results I've witnessed in patients treated during the trial have been very encouraging. Now that FDA clearance is in place, it's a pleasure, as a breast surgeon, to be able to offer this minimally invasive choice to appropriate patients — in particular, women whose breast cancer is low-risk and who are 70 years of age or older, plus those who might not be good candidates for surgery. In my conversations with colleagues, including at medical conferences, where I've presented the ICE3 data and given hands-on training, I've noticed a high level of interest among surgeons and radiologists alike. Cryoablation is increasingly being recognized as a minimally invasive option within the wider treatment landscape, and many physicians want to understand better how they can bring it into their clinical practice. Another key factor driving this interest is the growing volume of independent clinical research. Seeing such large numbers of investigator-initiated studies aimed at a single system is somewhat unusual. And here, ProSense is being used across numerous completed and ongoing studies. This degree of academic engagement is meaningful and mirrors a broader interest within the clinical community. With FDA clearance now in place for low-risk breast cancer, ProSense is turning into a natural choice for researchers who want to study cryoablation in this setting. On top of that, the updated 2026 resource guide from the American Society of Breast Surgeons, which recommends cryoablation as an option for selected patients with biologically low-risk breast cancer, marks an important step forward. Clinically speaking, guidance of this kind helps support informed decision-making and contributes to the broader adoption of new treatment approaches. Thank you.
Eyal, I believe you said there are 19 active sites at present. At what point do you anticipate reaching 30? What's your current best guess? Also, regarding bringing those sites online, would you say you're on schedule or ahead of schedule?
Shad, could you address that, please.
Yeah. Anthony, I just want to make sure — when you say that, do you mean the commercial sites? Or are you talking about the sites for the post-market study?
Regarding the post-market study locations — every one of those sites is also anticipated to be commercial scale, is that right?
That's right. Yes. So, given that the FDA protocol came through and got the green light in March, we've genuinely shifted into the following stage for this — for the post-market study — where we're beginning to sign agreements with sites across the country. Over the past couple of months, we've achieved some quite solid headway, and the advancement we've made leaves us feeling encouraged.
Anthony, we would say it's on schedule?
Yes, Anthony, we think we're going to stay on schedule. That means prior to September 5, since the FDA gave the protocol its approval by March, we'll have patient number one, and we expect and intend to enroll all 80 patients prior to March 27.
All right. Now moving over to Health Canada. You filed an amendment back in March, correct? Has any response come through yet? And are you still anticipating that Health Canada will reach a decision prior to the year's close?
Correct. What came to us was mostly a set of technical and informal inquiries, and we've answered them. Our expectation is that within the coming few weeks, they may return with additional questions, and we anticipate securing their approval ahead of the year's end.
All right. Now let's turn to Japan. Does Terumo remain on track to file by the close of June, or is the expectation the end of June?
My understanding is that it could be — during January, they held highly favorable talks with the Japanese FDA, the PMDA. They should be having the second call very shortly, as I understand it. Whether it lands at the end of June or in the early part of the third quarter, I can't say for certain yet, but they are moving at full speed toward that submission.
Alright. And I recognize, clearly, that there's a lot of intense attention — rightly so — on the breast cancer sector given the recent clearance and the aim to get those sites operational as quickly as possible; however, you also had some excellent kidney data, the ICESECRET study. So could you speak a bit about the R&D or the resources beyond breast cancer and how that's moving along, just broadly speaking?
Yes. As we've also talked about before, Anthony, the U.S. will concentrate on breast, while in Europe and other markets, we're also treating additional organs. Of course, following the FDA, and as we noted in the earnings call or earnings release, we have quite good activity in breast within Europe, but we're routinely treating other organs too in Europe and in Asia. And last November, if everyone recalls, Dr. Moi published a new study concerning lung cancer; so outside the U.S., we're treating all of them.
I have a couple of questions. The first one is, what portion of those active sites are going to be ChoICE sites?
Sure. Looking at the business we have right now, among the sites currently active, roughly 50% intend to take part in the ChoICE study.
All right, that's great. Actually, I've got something to ask Dr. Fine. As you wait for the CPT1 code to be issued, how do you plan to make use of ProSense, or at minimum, what do you anticipate your utilization of it will look like?
Are you referring to the ChoICE trial specifically, or just generally speaking?
So, when I look at it from a business standpoint — obviously, during the trial you'd be getting reimbursed — but suppose you've got patients who aren't in the trial. Does treating those people make financial sense? Is that something you can actually do?
Absolutely. A number of sites, and this is also our own plan once we go commercial, have chosen to perform this in an office setting rather than at a hospital. The pass-through code referenced a moment ago is not applicable in that office context. Even so, we and others have found that simply talking through the procedure with the patient and explaining what their out-of-pocket cost would look like works well. Since performing the procedure doesn't carry a particularly large total cost, a patient is generally able to handle paying something out of pocket in order to undergo it. And motivation levels among these patients tend to run high. Does that address what you were asking?
Yeah. So, quickly adding to what was just said — would it be fair to say that essentially every one of your commercial patients is answering yes?
I'd say that, up to now, everyone we've performed this on has responded affirmatively. Nobody has turned us down yet. That said, we are in the middle of significantly expanding the commercial side of this right now. So I'll have a clearer picture on that soon — and quite soon, actually, since the moment the FDA clearance came through, people started reaching out to us. Also, there was a piece — pardon me — a Reuters article that ran and then got picked up in Boston, and I expect more like it will appear across the country. I've even fielded a few inquiries already from patients nearby who saw it on the West Clinic website, where they put up the Boston piece.
I have a few things to ask. To start, my understanding is that the CPT1 code has to be turned in during June — do you foresee any obstacles to meeting that June deadline? Or at this stage is it basically an administrative matter?
Scott, I'll take that one. Thank you; we — because of Dr. Fine, who has also been heading up and continues to head the CPT code effort at the ASBrS, along with backing from other societies, our view is that there is more involved in this process. All of our clinical evidence is in hand. The package is currently undergoing its final refinement and polishing, and we intend to file it within 2 to 4 weeks; after that there will be a process, something like a questionnaire directed at the physician. Our expectation is that sometime during '27 we will receive approval, and this CPT1 code is meant to take effect on January 1, 2028.
All right, that's helpful. I'm not sure whether this is something you normally share, but would you be able to discuss how many placements occurred during the quarter? Also, could you describe the pattern we ought to anticipate across the quarters of 2026 — is it likely to be a gradual ramp, or might there be an inflection point? At times things move slowly for a while, and then that inflection point appears. I'm just attempting to understand how we should frame that cadence.
IceCure does provide guidance regarding sales leading to placement, yet we anticipate a fairly strong second quarter, and growth will keep going. Typically, the third quarter is somewhat slower owing to the summer holiday. The fourth quarter is a solid quarter, but growth is what we anticipate. We expect to see agreements with a site for the post-market study, and additionally that site being commercial, or certain sites, as Shad referenced, will be commercial only and won't take part in the post-market study, since they lack the facility needed to support some type of clinical process.
I wanted to jump in on that as well; with the FDA approval now in hand, many of those accounts we've been in discussions with are suddenly far more actionable. So across the country, we're engaged with a large number of accounts as they go through their purchasing processes to get cryoablation programs up and running. They're putting together business plans in support of that. As a result, we'd anticipate continuing to build momentum quarter-over-quarter.
All right, that's helpful. Now, turning to the ChoICE post-marketing study — assuming roughly 15 of the 30 sites are up and running already. As you pursue those remaining 15 sites, can you be selective, targeting places with heavy patient volume that you'd want in the trial, while at the same time establishing a presence at high-volume centers? Is that one of your goals too? And separately, could you share what we should expect to gain from the post-marketing study — obviously it will be far more real-world in nature — but we'd love to hear some of the insights that might come out of it.
Shad, perhaps you can take the first question, and Dr. Fine can speak to the type of clinical evidence we'll get from the PMS.
When it comes to the first portion of what you asked, about volume, our data sets are quite strong. We therefore possess a solid, distinct picture of the locations nationwide where these procedures take place. Clearly, we are working to position ourselves for the post-market study, and beyond that, for the commercial push involving a number of these sites across the country. Naturally, we would prefer those sites to be high volume too, since that assists us in reaching our objectives, both on the commercial side and for the study. Rich Fine, would you like to speak to the second portion of the question?
Right. My feeling is that the ChoICE post-market study will simply end up verifying what ICE3 already showed. In fact, the patient population the FDA let us treat is fairly favorable. The individuals who did best in ICE3 are exactly the ones who will be enrolled in the post-market study. So my expectation is that the outcomes we see will be extremely strong, and that they will serve to confirm the findings and, with luck, let the FDA begin widening the indications.
So in closing, we see the opening three months of 2026 as a significant move ahead for IceCure; there is clear proof that what we have established across the last several years — clinical data, regulatory milestone, and physician engagement — is at this point converting into commercial growth, especially within the U.S. When you put FDA clearance together with supporting clinical guidelines, growing reimbursement, and rising awareness among physicians and patients, you get a powerful setting for ProSense to keep being adopted. The expansion of our activities account base, the strength of our commercial pipeline, and the growing engagement throughout the medical community are all encouraging to us. We're eager to keep building on this momentum all through 2026. Thank you all for your time today.
That brings an end to the IceCure First Quarter 2026 Results Conference Call. We appreciate everyone taking part. At this point, feel free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IceCure Medical Ltd transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IceCure Medical Ltd earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.